Good morning. Don't forget to join us at 8am today for Beyond 2020: Making Care Affordable.
Today's word count: 860 words, <4 minutes.
Illustration: Rebecca Zisser/Axios
Virtual health care is all the rage right now, especially among investors and tech companies.
The big picture: Digital health tools have the potential to improve care.
What they're saying: "It's an area where implications for health care spending are wide open," the American Enterprise Institute's Ben Ippolito.
The bottom line: "One should never underestimate the health care system's ability to make money," the Kaiser Family Foundation's Larry Levitt said.
Enbrel, Pfizer's blockbuster anti-inflammatory drug, appeared to reduce the risk of Alzheimer's disease, but the company didn't investigate further or make the connection public, WashPost reports.
Pfizer says the decision not to conduct a clinical trial was based solely on science, and it didn't publish its data because it was skeptical about the results.
Some scientists say that just publishing the data could have been useful to researchers.
CVS' ambitions keep growing, but skepticism about those ambitions isn’t going away, Axios' Sam Baker writes.
Driving the news: Federal Judge Richard Leon signaled Tuesday that he's still concerned about the company's $69 billion merger with Aetna.
Between the lines: The Aetna deal is just one element of CVS' effort to push beyond the traditional role of a pharmacy.
What's next: CVS said Tuesday that it's expanding its HealthHub concept — stores with more space devoted to clinic services like screenings and dietary consultations.
The bottom line: There's big money in managing chronic diseases, especially as the population ages. And CVS is by no means the only company that's also hoping it can find big savings by moving more of that work under one corporate umbrella.
A new EvaluatePharma report reiterates just how heavily the pharmaceutical industry is banking on oncology.
Why it matters: The report also adds more evidence that drugs are getting more costly, and these costs will increasingly be driven by medicines with little to no competition.
Go deeper: The drug pricing debate is stuck in the past
Congress will leave in place a ban on genetically modified human embryos, despite a push to overturn it, Stat News reports.
Where it stands: Since 2015, Congress has effectively banned a procedure that combines genetic material from a mother, father and female donor.
The other side: Advocates for the ban say it prevents genetically altered "CRISPR babies."
Have a great Wednesday. Keep sending me tips and feedback.